Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · November 04, 2024

Efficacy and Safety of Trastuzumab Deruxtecan Plus Nivolumab in Patients With HER2-Expressing Metastatic Breast or Urothelial Cancer

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Trastuzumab Deruxtecan With Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
Clin. Cancer Res 2024 Oct 15;[EPub Ahead of Print], E Hamilton, MD Galsky, S Ochsenreither, G Del Conte, M Martín, MJ de Miguel, EY Yu, A Williams, M Gion, AR Tan, L Agrawal, A Rutten, JP Machiels, S Cresta, PR Debruyne, A Hennequin, V Moreno, A Minchom, F Valdes-Albini, D Petrylak, L Li, Z Tsuchihashi, F Suto, FC Cheng, M Kandil, D Barrios, S Hurvitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading